PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.48
Negative P/E while Biotechnology median is -1.97. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
1.20
P/B 50-90% of Biotechnology median of 1.78. Mohnish Pabrai would examine if this discount presents opportunity.
-6.83
Negative FCF while Biotechnology median P/FCF is -7.56. Seth Klarman would investigate cash flow improvement potential.
-6.83
Negative operating cash flow while Biotechnology median P/OCF is -7.40. Seth Klarman would investigate operational improvement potential.
1.20
Fair value ratio 50-90% of Biotechnology median of 1.78. Mohnish Pabrai would examine if this gap presents opportunity.
-16.92%
Negative earnings while Biotechnology median yield is -6.63%. Seth Klarman would investigate path to profitability.
-14.63%
Negative FCF while Biotechnology median yield is -4.52%. Seth Klarman would investigate cash flow improvement potential.